Close Menu

NEW YORK – Sermonix Pharmaceuticals announced on Tuesday that it had dosed the first patient in a Phase II clinical trial of its investigational drug, lasofoxifene, in combination with CDK 4/6 inhibitor abemaciclib (Eli Lilly's Verzenio).

The trial, called ELAINE 2, will evaluate lasofoxifene, a selective estrogen receptor modulator, in combination with abemaciclib in pre- and postmenopausal women with locally advanced, metastatic, estrogen receptor-positive, HER2-negative breast cancer and an ESR1 mutation in their tumors. The primary endpoint is progression-free survival.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.


Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.


Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.


This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.